(E)-2-(4-fluorostyryl)benzonitrile

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (E)-2-(4-fluorostyryl)benzonitrile
• 英文别名: 2-[(E)-2-(4-fluorophenyl)ethenyl]benzonitrile
• 化学式: C₁₅H₁₀FN
• 分子量: 223.25
• InChiKey: QGZBTKWXEYUFKE-VMPITWQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-2-(4-fluorostyryl)benzonitrile 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 以67%的产率得到2-(3-(4-fluorophenyl)oxiran-2-yl)benzonitrile
  参考文献：
  名称：

  碳催化官能化腈的钯催化串联CC活化/环化反应：苯并双嘧啶的合成。

  摘要：

  据报道，钯催化的2-（3-苯基环氧乙烷-2-基）苄腈与芳基硼酸的碳-碳键活化反应。通过该反应中的β-碳消除，裂解并重建了多个化学键，从而能够构建有价值的苯并熔合的双嘧啶，这是其他方法难以制备的。此外，合成了一系列苯并硼化的双吡啶并蒽，在扩大荧光材料的应用和类型方面显示出实际的意义。初步的机理实验为所提出的机理提供了支持。

  DOI：

  10.1021/acs.orglett.0c02478
• 作为产物：
  描述：

  苯甲腈 在 羰基镁 、 特戊酸钠 、 乙酰氯 作用下， 以 乙二醇二甲醚 为溶剂， 反应 4.0h， 生成 (E)-2-(4-fluorostyryl)benzonitrile
  参考文献：
  名称：

  锰催化的芳族NH-酰亚胺亚胺与炔烃的邻位CH-H烯基化反应：多功能获得单烯化芳族腈的途径

  摘要：

  到目前为止，还没有实现芳族腈与炔烃的直接CH H烯基化。在本文中，我们描述了芳族N-酰亚胺的锰催化的CH-H烯基化反应，从而获得了单烯基化的芳族腈。通过催化量的新戊酸钠的存在促进反应。简单的催化体系，良好的官能团相容性，出色的单/二烯基化选择性以及E / Z立体选择性也突出了该方案。

  DOI：

  10.1002/adsc.201600128

文献信息

• Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US20020004522A1

  公开（公告）日：2002-01-10

  Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

  本发明涉及一种用于治疗患有神经系统疾病或障碍的患者的方法和组合物，例如中风、头部创伤、脊髓损伤、脊髓缺血、缺血或缺氧引起的神经细胞损伤、癫痫、焦虑、神经精神或认知缺陷，由于缺血或缺氧而经常发生在心脏手术下心肺转流的后果，或神经退行性疾病，例如阿尔茨海默病、亨廷顿病、帕金森病或肌萎缩侧索硬化症（ALS）。
• Dibenzocycloheptenylidenes
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0115690A1

  公开（公告）日：1984-08-15

  Compounds having the formula: wherein R4 is hydrogen or chloro; R5 is carboxy, an ester thereof, or tetrazolyl; R2 is hydrogen, halo, or alkoxy of 1 to 4 carbon atoms; and R3 is hydrogen or bromo, with the proviso that when R4 is hydrogen, R5 is carboxy and R2 or R3 is other than hydrogen; and that when R4, R2 and R3 are all hydrogen, R5 is tetrazolyl; the stereoisomers thereof and the pharmaceutically acceptable salts thereof. The compounds of formula B wherein R5 is carboxy or tetrazolyl have pharmaceutical utility eg. as anti-inflammatory agents. The compounds where R5 is a carboxylic ester are intermediates for the corresponding acids. Pharmaceutical composition containing the active compounds are also disclosed.

  具有以下式子的化合物 其中 R4 为氢或氯； R5 是羧基、其酯或四唑基 R2 是氢、卤素或 1 至 4 个碳原子的烷氧基；以及 R3 是氢或溴，但当 R4 是氢时，R5 是羧基，R2 或 R3 不是氢；当 R4、R2 和 R3 都是氢时，R5 是四唑基；其立体异构体及其药学上可接受的盐。其中 R5 为羧基或四唑基的式 B 化合物具有医药用途，例如可用作抗炎剂。R5 为羧酸酯的化合物是相应酸类的中间体。还公开了含有活性化合物的药物组合物。
• Aryl isonitrile compounds as a new class of potent, broad-spectrum antifungal compounds
  申请人：Purdue Research Foundation

  公开号：US10449174B2

  公开（公告）日：2019-10-22

  Invasive fungal infections present a formidable global public health challenge due to the limited number of approved antifungal agents and the emergence of resistance to the frontline treatment options, such as fluconazole. Three fungal pathogens of significant concern are Candida, Cryptococcus, and Aspergillus given their propensity to cause opportunistic infections in immunocompromised individuals. This disclosure provides a set of aryl isonitrile compounds that possess broad-spectrum antifungal activity primarily against species of Candida and Cryptococcus. The most potent derivatives are capable of inhibiting growth of these key pathogens at concentrations as low as 0.5 μM. Remarkably, the most active compounds exhibit an excellent safety profile and are non-toxic to mammalian cells even at concentrations up to 256 μM.

  由于获批的抗真菌药物数量有限，而且对氟康唑等一线治疗药物出现了抗药性，因此侵袭性真菌感染给全球公共卫生带来了严峻的挑战。由于白色念珠菌、隐球菌和曲霉菌容易引起免疫力低下人群的机会性感染，因此这三种真菌病原体备受关注。本公开提供了一组具有广谱抗真菌活性的芳基异腈化合物，主要针对念珠菌和隐球菌。最有效的衍生物能够在低至 0.5 μM 的浓度下抑制这些主要病原体的生长。值得注意的是，最有效的化合物具有极佳的安全性，即使浓度高达 256 μM 也不会对哺乳动物细胞产生毒性。
• ARYL ISONITRILE COMPOUNDS AS A NEW CLASS OF POTENT, BROAD-SPECTRUM ANTIFUNGAL COMPOUNDS
  申请人：Purdue Research Foundation

  公开号：US20170181997A1

  公开（公告）日：2017-06-29

  Invasive fungal infections present a formidable global public health challenge due to the limited number of approved antifungal agents and the emergence of resistance to the frontline treatment options, such as fluconazole. Three fungal pathogens of significant concern are Candida, Cryptococcus , and Aspergillus given their propensity to cause opportunistic infections in immunocompromised individuals. This disclosure provides a set of aryl isonitrile compounds that possess broad-spectrum antifungal activity primarily against species of Candida and Cryptococcus . The most potent derivatives are capable of inhibiting growth of these key pathogens at concentrations as low as 0.5 μM. Remarkably, the most active compounds exhibit an excellent safety profile and are non-toxic to mammalian cells even at concentrations up to 256 μM.
• US6211245B1
  申请人：——

  公开号：US6211245B1

  公开（公告）日：2001-04-03